No matches

6 search results for: standard of care

Loss <b>of</b> Smell is a Key Symptom <b>of</b> CRSwNP

Rhinology

Loss of Smell is a Key Symptom of CRSwNP

5 min

interactivity

Learn how loss of smell in CRSwNP is a key symptom for both patients and providers.

Rhinology

ERS-ISIAN 2025 | Disease Control in CRSwNP

10 min

expert video

Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.

Dermatology

Urticaria Guidelines Recommend the Assess, Act/Adjust, and Reassess Principles

2 min

expert video

Dr. Jason Hawkes discusses the guidelines for chronic spontaneous urticaria and how they will impact patient management.

Dermatology

Insights From Dr Lawrence Eichenfield on the 2026 IEC Consensus Definition for Low Disease Activity and Remission for Atopic Dermatitis

2 min

expert video

Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: EstoniaChange country/region